

The ENABLE project

Funding and supporting European antibacterial drug discovery against gram negative pathogens

www.nd4bb-enable.eu

ENABLE – Introduction

Public private partnership in Europe

Innovative Medicines Initiative: Joint private (EFPIA) and public (European Commission) effort to address key bottlenecks in healthcare improvement

European consortium to develop novel anti-infectives

Core consortium of expert partners for the development of anti-infectives to clinic - including universities, small companies and EFPIA companies

€85 million over 6 years to fund novel programmes to clinic

- Funding for novel gram negative programmes to join the project
- Programme owners work in collaboration to accelerate programmes to clinic
- 3.5 years left on the clock

ENABLE – Goals and Objectives

The challenge:

One of the major challenges in antibiotic discovery is turning Hits and Leads into development candidates – finance, skills, route to clinic and market

ENABLE Objectives :

Increase the overall pipeline in the antibacterial area through external programmes feeding into a development ‘engine’

ENABLE Goals:

Target the systemic treatment of infections due to resistant Gram-negative bacterial pathogens *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*

- identify three antibacterial Leads
- identify two antibacterial development Candidates
- progress at least one compound into Phase 1 clinical studies

ENABLE – what does it look like?

- Gram negative programmes with data to indicate potential submit 3 page expression of interest to the project – single applicant
- Thresholds to meet – MIC, cytotox etc, demonstrate potential and innovation
- Reviewed by external experts to assess fit to thresholds
- Develop detailed data pack for presentation to the Portfolio Management Committee (PMC)
- If approved – collaborative workplan developed and costed
- Programme owner joins consortium as a formal partner
- Targets set by the PMC to meet
- Reviewed each three months by PMC to assess progress
- If targets met, green light
- If targets missed, programme adaptation or termination

ENABLE – let's talk money

- Eligible for funding: Small companies, universities and research organisations within the EU and associated countries such as Israel, Norway and Switzerland
- Individual programmes have a budget split between the 3-4 partners working upon them; each partner will receive funding for their work
- Eligible costs include direct costs (staff, consumables) plus a 20% indirect cost - funded at 75%
- All work approved for each programme is eligible, including clinical trials
- Subcontracting possible for skills not found within consortium – contract with programme owner

ENABLE – IP and exploitation

- Critical that programmes are able to reach market – not just science but also investment and future partnerships
- All IP associated with programme is retained by programme owner – including new IP generated within the project
- Partners have access to foreground IP for delivery of project activities but no permission for non-programme use
- Limited revenue sharing when cash generated by programme (as all partners contribute financially) – small % of income with cap on maximum dependant on how much ENABLE has contributed to development

IMI eligible partners

- To be eligible for IMI funding, organisations must be EU registered, small companies, research organisations or non-profit organisations
- HOWEVER – non-SMEs and other European organisations can participate in ENABLE with programmes, they do not receive funds for their own role in the development programme
- Priority to EU- based programmes, funded by the EU taxpayer...
- Programmes will also be approved based on ENABLE portfolio – minimise duplication
- If non-EU?
 - Licence programmes into EU partners, examples in project already
 - Come to Europe! The food and company are great!

Next step

- Talk to me and ENABLE colleagues (Frederik Deroose) – Not a one size fits all programme
- Advice in confidence
- www.nd4bb-enable.eu/open-calls
- Support through generation of EoI
- Claire Skentelbery – cs@European-biotechnology.net

